Antonio Rossi Selected Research

Gefitinib (Iressa)

12/2017	Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer.
1/2017	Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.
1/2014	Irreversible EGFR inhibitors in the treatment of advanced NSCLC.
8/2013	Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
1/2013	New molecular targets in the treatment of NSCLC.
1/2011	Factors driving the choice of the best second-line treatment of advanced NSCLC.
8/2007	Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
3/2005	Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases.
7/2004	The role of targeted therapy in non-small cell lung cancer.
5/2004	Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Antonio Rossi Research Topics

Disease

118	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 03/2003
60	Neoplasms (Cancer) 02/2024 - 07/2004
29	Lung Neoplasms (Lung Cancer) 11/2023 - 03/2003
19	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2024 - 06/2002
14	Osteogenesis Imperfecta (Lobstein Disease) 10/2023 - 06/2007
12	Infections 12/2023 - 12/2006
12	Diastrophic dysplasia 10/2023 - 07/2003
11	Disease Progression 05/2022 - 06/2007
10	Neoplasm Metastasis (Metastasis) 02/2024 - 03/2003
9	Type 2 Diabetes Mellitus (MODY) 12/2023 - 08/2016
8	COVID-19 04/2022 - 12/2020
8	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 01/2002
7	Vomiting 01/2019 - 01/2002
7	Prolidase Deficiency 03/2015 - 09/2003
5	Mycoses (Diseases, Fungus) 01/2024 - 11/2008
5	Nausea 01/2019 - 01/2002
4	Adenocarcinoma of Lung 02/2024 - 05/2005
4	Desbuquois syndrome 08/2021 - 10/2010
4	Adenocarcinoma 02/2017 - 05/2010
4	Carcinogenesis 01/2013 - 09/2003
4	Breast Neoplasms (Breast Cancer) 12/2008 - 03/2003
3	Starvation 12/2023 - 04/2007
3	Body Weight (Weight, Body) 12/2023 - 01/2021
3	Hypoglycemia (Reactive Hypoglycemia) 12/2023 - 07/2020
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/2022 - 01/2022
3	Congenital Abnormalities (Deformity) 01/2017 - 07/2010
3	Diarrhea 08/2013 - 01/2002
3	Omani type Spondyloepiphyseal dysplasia 08/2012 - 06/2008
3	Neutropenia 10/2009 - 01/2002
2	Tinea (Ringworm) 05/2024 - 01/2015
2	Root Resorption 02/2024 - 01/2023
2	Albuminuria 12/2023 - 01/2022
2	Heart Failure 12/2023 - 01/2022
2	Carcinoid Tumor (Carcinoid) 09/2023 - 05/2019

Drug/Important Bio-Agent (IBA)

28	ErbB Receptors (EGF Receptor)IBA 11/2023 - 05/2004
18	Tyrosine Kinase InhibitorsIBA 11/2023 - 05/2004
18	Erlotinib Hydrochloride (CP 358,774)FDA Link 12/2017 - 01/2007
16	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2004
15	PlatinumIBA 01/2017 - 11/2005
13	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 01/2003
12	Monoclonal AntibodiesIBA 02/2024 - 01/2004
10	Glucose (Dextrose)FDA LinkGeneric 12/2023 - 05/2016
10	Bevacizumab (Avastin)FDA Link 01/2020 - 10/2007
10	Gefitinib (Iressa)FDA Link 12/2017 - 05/2004
9	CollagenIBA 10/2023 - 06/2006
8	Biomarkers (Surrogate Marker)IBA 10/2023 - 09/2011
8	Sulfates (Sulfates, Inorganic)IBA 10/2023 - 07/2003
8	Collagen Type I (Type I Collagen)IBA 01/2023 - 07/2009
8	EnzymesIBA 01/2020 - 08/2007
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 10/2007
8	Cetuximab (Erbitux)FDA Link 06/2018 - 08/2006
8	Pemetrexed (MTA)FDA Link 01/2017 - 03/2007
8	Gemcitabine FDA Link 03/2014 - 03/2007
7	Immune Checkpoint InhibitorsIBA 02/2024 - 12/2014
7	Sulfate TransportersIBA 01/2023 - 07/2003
7	proline dipeptidase (prolidase)IBA 03/2015 - 06/2005
6	pembrolizumabIBA 02/2024 - 01/2016
6	Anaplastic Lymphoma KinaseIBA 10/2022 - 03/2013
5	GlycosaminoglycansIBA 10/2023 - 01/2017
5	CytokinesIBA 01/2023 - 05/2007
5	VaccinesIBA 04/2022 - 09/2009
5	Fluorouracil (Carac)FDA LinkGeneric 05/2003 - 01/2002
4	Keratins (Keratin)IBA 12/2023 - 07/2009
4	osimertinibIBA 11/2023 - 12/2017
4	ChloridesIBA 10/2023 - 07/2003
4	LigandsIBA 12/2022 - 12/2014
4	Proteasome InhibitorsIBA 02/2021 - 05/2014
3	Carboplatin (JM8)FDA LinkGeneric 02/2024 - 06/2002
3	CarbonIBA 12/2023 - 02/2010
3	dapagliflozinIBA 12/2023 - 01/2021
3	AntiportersIBA 10/2023 - 07/2003
3	DNA (Deoxyribonucleic Acid)IBA 09/2023 - 01/2015
3	Proteoglycans (Proteoglycan)IBA 10/2022 - 07/2010
3	Insulin (Novolin)FDA Link 07/2022 - 12/2020
3	Peptide Hydrolases (Proteases)FDA Link 01/2022 - 06/2005
3	Bortezomib (Velcade)FDA Link 02/2021 - 05/2014
3	Acetylcysteine (Siran)FDA LinkGeneric 01/2021 - 10/2015
3	Liraglutide FDA Link 01/2021 - 08/2016
3	Angiogenesis InhibitorsIBA 01/2019 - 10/2007
3	SulfotransferasesIBA 01/2019 - 10/2010
3	AfatinibIBA 12/2017 - 08/2013
3	Docetaxel (Taxotere)FDA Link 04/2017 - 01/2011
3	Phosphotransferases (Kinase)IBA 01/2013 - 02/2007
3	Phosphates (Orthophosphate)IBA 10/2008 - 04/2007
3	Vinorelbine (Navelbine)FDA LinkGeneric 03/2003 - 06/2002
3	Leucovorin (Folinic Acid)FDA Link 03/2003 - 01/2002
2	Paclitaxel (Taxol)FDA LinkGeneric 02/2024 - 04/2008
2	Programmed Cell Death 1 ReceptorIBA 02/2024 - 12/2014
2	semaglutideIBA 12/2023 - 01/2021
2	CreatinineIBA 12/2023 - 01/2022
2	Immunoconjugates (Immunoconjugate)IBA 11/2023 - 04/2023
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 07/2023 - 08/2006
2	CationsIBA 01/2023 - 05/2014

Therapy/Procedure

59	Therapeutics 02/2024 - 09/2003
58	Drug Therapy (Chemotherapy) 05/2024 - 01/2003
18	Immunotherapy 02/2024 - 12/2014
5	Radiotherapy 12/2021 - 05/2005
4	Adjuvant Chemotherapy 07/2011 - 01/2007
2	Neoadjuvant Therapy 02/2024 - 07/2021
2	Glycemic Control 12/2023 - 01/2022